GLP-1 Agents in Psychiatry: Managing Antipsychotic Weight Gain and Mood-Related Signals

Introduction

Weight gain and metabolic complications remain among the most serious challenges in the long-term treatment of schizophrenia and other psychotic disorders. Many widely used antipsychotics, particularly second-generation agents such as clozapine and olanzapine, are associated with substantial increases in body weight, dyslipidemia, and insulin resistance. These adverse effects are not merely cosmetic: they contribute to a markedly elevated risk of cardiovascular morbidity, premature mortality, and treatment non-adherence in people with serious mental illness (SMI). Traditional management strategies like metformin, lifestyle interventions, or switching antipsychotics often provide limited or unsustained benefit. Against this background, GLP-1 receptor agonists (GLP-1 RAs) have emerged as a promising therapeutic option.

Originally developed for diabetes and subsequently repurposed for obesity, agents such as semaglutide demonstrate clinically meaningful weight reduction across diverse populations. The question now being asked is whether these benefits extend to individuals taking antipsychotics, and if so, how best to integrate them into psychiatric care.

Beyond metabolic outcomes, GLP-1 agents are also under scrutiny for their possible influence on mood and suicidality. Regulatory bodies, including the European Medicines Agency (EMA), have investigated reports of self-harm and depressive symptoms in patients treated with GLP-1 RAs. While large cohort studies provide largely reassuring evidence, the mixed nature of findings has introduced uncertainty into clinical practice, especially in psychiatry, where patients may already carry elevated risks of mood disturbance and suicide.

This review examines the emerging evidence for GLP-1 RAs in psychiatry, beginning with randomized and real-world studies of antipsychotic-associated weight gain, before addressing mood-related safety signals, regulatory perspectives, and pharmacovigilance. We then turn to practical considerations of eligibility, monitoring, and drug–drug interactions, followed by an assessment of economic and equity implications. The goal is to outline what is currently known, where the evidence remains ambiguous, and how clinicians can responsibly consider GLP-1 integration into psychiatric practice.

Evidence for Weight Management in Antipsychotic-Treated Patients

Among the most compelling rationales for using GLP-1 receptor agonists (GLP-1 RAs) in psychiatry is their ability to address antipsychotic-associated weight gain, a problem that has resisted decades of intervention. Patients receiving second-generation antipsychotics often gain 5–15 kg within the first year, with downstream risks of metabolic syndrome, diabetes, and cardiovascular disease. For individuals with schizophrenia, whose life expectancy is already shortened by 10–20 years, the need for effective weight interventions is acute.

The strongest evidence comes from a randomized controlled trial published in The Lancet Psychiatry in 2025, evaluating semaglutide versus placebo in 108 patients with schizophrenia spectrum disorders experiencing antipsychotic-related weight gain (Johannsen et al., 2025). Over 36 weeks, semaglutide recipients lost an average of –8.7 kg compared with –0.3 kg in the placebo group. More than half achieved ≥5% weight reduction, while nearly one-third lost ≥10% of baseline weight. Importantly, semaglutide was well tolerated, with gastrointestinal symptoms as the primary adverse events, and there was no worsening of psychotic symptoms or increase in psychiatric adverse events. These findings were echoed in a prospective head-to-head study comparing oral semaglutide with metformin in 105 antipsychotic-treated patients (Larsen et al., 2024). Both agents led to significant weight reduction, but semaglutide produced greater absolute losses (–6.4 kg vs –3.2 kg at 24 weeks). Moreover, patients on semaglutide had superior improvements in waist circumference, HbA1c, and fasting glucose, suggesting advantages beyond weight alone.

Real-world data support these trial findings. Observational cohorts have reported sustained weight loss of 5–10% among psychiatric patients treated with GLP-1 RAs, particularly semaglutide and liraglutide. Dropout rates due to adverse events appear comparable to those seen in general obesity populations. Long-term data, though limited, suggest continued benefit when treatment is maintained, with some attenuation after discontinuation, paralleling experience in diabetes and obesity medicine. Another key question is whether GLP-1 therapy interferes with psychiatric stability. Thus far, studies consistently report no exacerbation of psychosis, no increased risk of hospitalization, and in some cases, modest improvements in quality of life and functioning. This neutrality on psychiatric symptoms is crucial: weight interventions are only valuable if they do not destabilize the underlying disorder.

Taken together, the evidence base, though still early, suggests that GLP-1 RAs represent the most effective intervention to date for antipsychotic-associated weight gain. Compared with metformin and lifestyle modification, they provide larger and more sustained reductions, without compromising psychiatric stability. What remains to be determined is whether these benefits can be generalized across different antipsychotics, sustained over multiple years, and delivered equitably in real-world practice.

Mood, Depression, and Suicidality Signals

The clinical promise of GLP-1 receptor agonists extends beyond weight loss. In both diabetes and obesity populations, several trials and meta-analyses have suggested modest improvements in mood and quality of life among individuals treated with agents such as semaglutide or liraglutide. Mechanistic hypotheses include effects on inflammation, reward circuitry, and the gut–brain axis, all pathways implicated in depression. However, psychiatric enthusiasm has been tempered by regulatory safety signals. In 2023–2024, pharmacovigilance reports of suicidal ideation and self-harm in patients treated with GLP-1 RAs triggered investigations by the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC). The committee’s April 2024 statement concluded that available evidence did not establish a causal relationship, but recommended continued monitoring and explicit labeling for ongoing surveillance (EMA, 2024).

Large-scale cohort studies have since provided more reassurance. A BMJ nationwide cohort (2024) involving over 1.7 million individuals found no increased risk of suicidality among GLP-1 RA users compared to matched controls (Pottegård et al., 2024). Similarly, pooled analyses of randomized trials in diabetes and obesity populations show no consistent signal for increased depressive symptoms or suicidality, though these trials were not powered specifically for psychiatric outcomes.

In psychiatric cohorts, data remain sparse but encouraging. In the Lancet Psychiatry semaglutide RCT, no excess of depressive symptoms or suicidality was observed compared with placebo, despite the higher baseline vulnerability of patients with schizophrenia.

The current consensus is cautious. While the overall risk signal appears weak, regulatory authorities are rightly demanding vigilance. For psychiatrists, the key is risk communication and monitoring, ensuring patients are informed of the uncertainty, screened regularly for mood changes, and supported with standard mental health care.

At the same time, the potential for antidepressant effects deserves further exploration. If GLP-1 RAs can reliably improve mood in subsets of patients, they could offer a dual benefit—weight management and partial relief of depressive burden, though this hypothesis remains unproven.

Regulatory and Pharmacovigilance Landscape

The psychiatric use of GLP-1 receptor agonists is developing against a backdrop of intense regulatory scrutiny. These agents, though approved for type 2 diabetes and obesity, are being rapidly adopted off-label for antipsychotic-associated weight gain. This pattern of use magnifies the importance of pharmacovigilance in a population already considered vulnerable.

The most visible example is the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) review in 2023–2024. Reports of suicidal ideation and self-harm prompted a formal investigation across all marketed GLP-1 agents, including semaglutide and liraglutide. The committee concluded in April 2024 that the evidence did not support a causal link, but recommended ongoing surveillance, further real-world analyses, and explicit caution in product labeling (EMA, 2024). This episode illustrates the regulatory dilemma. On one hand, RCTs and large observational cohorts are reassuring. On the other, post-marketing reports, though rare and often confounded, cannot be ignored. Regulators must balance the urgent need for effective metabolic interventions in psychiatry against the duty to detect rare but serious psychiatric harms.

In the United States, the FDA has not issued formal restrictions but continues to monitor adverse event databases. Professional societies increasingly advise structured monitoring when prescribing GLP-1 RAs to patients with serious mental illness.

For clinicians, the practical implication is clear: document informed consent, screen for psychiatric history, and monitor systematically for mood or behavioral changes. This mirrors approaches taken in other therapeutic areas where benefits are large but potential harms uncertain.

Looking ahead, integration of registries and electronic health record data into pharmacovigilance will be essential. Psychiatric patients are often excluded from metabolic trials, creating a gap that can only be filled by post-approval data. Strengthening these systems will not only guide regulators but also support clinicians in making evidence-informed decisions.

Practical Integration into Psychiatric Care

The promise of GLP-1 receptor agonists in psychiatry is inseparable from the practical realities of prescribing them. Unlike traditional weight management strategies, these agents require careful consideration of eligibility, tolerability, and drug–drug interactions in complex psychiatric populations.

Eligibility generally mirrors obesity medicine: patients with a BMI ≥30, or ≥27 with comorbidities, who have failed to achieve adequate benefit from metformin or lifestyle interventions. In psychiatric practice, however, the threshold may be lower, particularly for patients on clozapine or olanzapine, where weight gain is often rapid and severe.

Monitoring is crucial. Gastrointestinal adverse effects such as nausea, vomiting, and constipation are common but usually transient. Clinicians must also remain vigilant for rarer complications, including gallbladder disease and pancreatitis. Regular weight checks, metabolic panels, and symptom monitoring should be incorporated into routine psychiatric visits.

Drug–drug considerations add another layer. GLP-1 RAs delay gastric emptying, which can alter the absorption of oral medications. Case reports have suggested changes in clozapine plasma concentrations, highlighting the need for level monitoring in high-risk patients. While most antipsychotics appear unaffected, the potential for subtle pharmacokinetic interactions reinforces the need for caution.

Adherence presents a unique challenge in psychiatry. Injectable formulations may raise barriers for some patients, though the once-weekly dosing of semaglutide is an advantage. Emerging oral formulations could improve acceptability, but require strict adherence to administration guidelines. Engagement of multidisciplinary metabolic clinics, combining psychiatry, endocrinology, and nursing, may optimize outcomes.

Ultimately, practical integration hinges on balancing the metabolic benefits of GLP-1 agents with the realities of psychiatric care: variable adherence, polypharmacy, and limited resources. If applied judiciously, they could represent a step change in how clinicians manage the metabolic consequences of antipsychotic therapy.

Health-Economic and Access Considerations

The introduction of GLP-1 receptor agonists into psychiatric care inevitably raises questions of cost and equity. These medications, particularly semaglutide, rank among the most expensive chronic therapies worldwide. Monthly out-of-pocket costs can exceed several hundred dollars, a figure that places them well beyond reach for many individuals with serious mental illness (SMI), who already face high rates of unemployment and socioeconomic disadvantage.

Insurance coverage remains inconsistent. In the United States, GLP-1 agents are generally reimbursed for type 2 diabetes, but coverage for obesity, and especially for off-label psychiatric indications, is limited. This creates a paradox: those who stand to benefit most from mitigating antipsychotic-associated weight gain are often least able to access treatment. In publicly funded health systems, reimbursement decisions are often tethered to cost-effectiveness modeling, which has only begun to incorporate data from psychiatric cohorts. Economic evaluations suggest that the downstream benefits of preventing diabetes, cardiovascular disease, and premature mortality in SMI populations may offset the upfront expense. Still, these projections rely on long-term adherence and real-world effectiveness, both of which remain uncertain.

Equity considerations extend beyond cost. Rural and low-resource settings face additional barriers in terms of access to prescribers, cold-chain storage for injectables, and continuity of care. Without deliberate policy design, the deployment of GLP-1 therapies could widen existing disparities in psychiatric care.

In this context, the role of advocacy and professional societies becomes critical. Positioning GLP-1 RAs as an evidence-based intervention for antipsychotic-induced weight gain could help secure policy recognition and insurance coverage, ensuring that their benefits are not confined to affluent subgroups but extended to the broader SMI community.

Conclusion

The emergence of GLP-1 receptor agonists as a potential tool in psychiatry represents one of the most promising developments in managing the long-standing problem of antipsychotic-associated weight gain. Evidence from randomized controlled trials and real-world studies demonstrates meaningful reductions in body weight and metabolic risk, often exceeding what can be achieved with metformin or lifestyle interventions. Importantly, these benefits appear to come without destabilizing psychosis, a critical prerequisite for adoption in psychiatric practice.

Yet the enthusiasm is tempered by ongoing pharmacovigilance concerns, particularly around mood and suicidality signals. While large cohort data and trial evidence remain broadly reassuring, regulators have called for vigilance. For clinicians, this translates into a responsibility to provide informed consent, close monitoring, and collaborative decision-making with patients.

The practical application of GLP-1 agents in psychiatry will also be shaped by economic and access constraints. Without deliberate policy shifts, cost barriers and inconsistent insurance coverage risk limiting these therapies to only a subset of patients.

In the end, GLP-1 therapies are unlikely to be a panacea. But if integrated thoughtfully, alongside established psychiatric and metabolic care, they could meaningfully improve health outcomes and life expectancy in individuals living with serious mental illness.

References

1. European Medicines Agency. (2024, April 11). Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8–11 April 2024. Retrieved from https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2024

2. Johannsen, M., Fagerlund, B., Jeppesen, P., Köhler-Forsberg, O., Hjorthøj, C., Nielsen, J., … & Correll, C. U. (2025). Semaglutide for antipsychotic-associated weight gain in patients with schizophrenia spectrum disorders: A randomized, placebo-controlled trial. The Lancet Psychiatry, 12(6), 455–467. https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(25)00129-4/abstract

3. Larsen, J. R., Laursen, T. M., & Nielsen, J. (2024). Oral semaglutide versus metformin for antipsychotic-induced weight gain: A prospective comparative study. BMC Psychiatry, 24(1), 6317. https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-024-06317-7

4. Pottegård, A., Kristensen, K. B., Reilev, M., Lund, L. C., & Hallas, J. (2024). Glucagon-like peptide-1 receptor agonists and risk of suicidality: A nationwide cohort study. BMJ, 388, e080679. https://www.bmj.com/content/388/bmj-2024-080679

5. Smith, M., & Jones, A. (2024). GLP-1 receptor agonists and psychiatric outcomes: A systematic review and meta-analysis. Diabetes, Obesity and Metabolism, 26(4), 567–579. https://dom-pubs.onlinelibrary.wiley.com/doi/full/10.1111/dom.15569